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Chapter 2
Drug-Related Infectious Diseases
Lucy Dillon and Mary O'Brien
2.1 Introduction
As in other European countries, the advent of HIV/AIDS and the connection
made between its spread and injecting drug use, can be seen to have played a
key role in influencing the development of drug-related policy and services in
Ireland (Butler, 1991; O'Gorman, 1998). Prior to the early 1990s, abstinence was
seen as the most acceptable goal for Irish drug-treatment programmes.
However, the early 1990s saw a move toward greater use of harm-reduction
strategies and the expansion of substitution and needle exchange programmes in
Irish drug-treatment services. The 1991 Government Strategy to Prevent Drug
Misuse confirmed both the shift in treatment philosophy from one based solely
on abstinence to one that included a harm-reduction strategy, and the central
role the advent of HIV had played in this policy shift: 
Insofar as HIV infection is concerned, of the 1,049 cases identified, 582 (or 57%)
are drug misuse related. … It is clear from the foregoing that the prevention of
transmission of HIV virus in this country must include strategies developed to
deal with the drug misuse problem. …These strategies must be community
based, client orientated and, given the serious nature of the problem, of
necessity, innovative. They must include emphasis on outreach programmes
involving counselling, methadone maintenance and needle exchange. Advice
on risk reduction services generally must form an essential part of any such
strategies to minimise the spread of the disease [HIV/AIDS]; (Government
Strategy to Prevent Drug Misuse, 1991: 7).
Furthermore, while the two reports produced by the Ministerial Task Force to
Reduce the Demand for Drugs  (1996, 1997) continued to reiterate the ultimate
aim of all treatment programmes as abstinence, harm-minimisation strategies,
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specifically aimed at preventing the spread of HIV (i.e. substitution and needle
exchange programmes), became a central feature of drug-treatment services. The
second report of the Task Force argued that it had developed 'a strong
philosophy of harm reduction and treatment of the consequences of drug abuse
- stabilisation, methadone maintenance, detoxification, rehabilitation and re-
integration' (Ministerial Task Force to Reduce the Demand for Drugs, 1997: 7). 
While HIV/AIDS may be seen as the drug-related infectious disease that was at
the centre of drug policy development in Ireland, other diseases, in particular
hepatitis C, are attracting an increasing amount of attention from those working
in the area. The following sections of this chapter will address three key issues
on drug-related infectious diseases in the Irish context:
2.2 Prevalence of HIV, HBV and HCV among Drug Users
2.3 Determinants of Drug-Related Infectious Diseases
2.4 Consequences of Drug-Related Infectious Diseases
2.5 New Developments and Uptake of Prevention/Harm Reduction and 
Care
2.2 Prevalence of HIV, HBV and HCV among Drug Users
Epidemiological analysis of drug-related infectious diseases in Ireland is
somewhat restricted by a lack of data. The gap in information is particularly
acute in relation to hepatitis B and C. The following sections will examine the
data that are available in relation to each of the relevant drug-related infectious
diseases: HIV, hepatitis B and hepatitis C. 
2.2.1  HIV
The majority of data collected on drug-related infectious diseases are related to
HIV. There are two main sources of data that will be discussed below: first, the
routine data on HIV-positive tests reported by the Department of Health and
Children; and second, special studies that have estimated the prevalence of HIV
among particular cohorts of drug users.
1985** 221 (60.9) 39 (10.7) 0 103 (28.4) 363 (100.0)
1986 112 (66.3) 11 (6.5) 21 (12.5) 25 (14.8) 169 (100.0)
1987 72 (49.7) 21 (14.5) 26 (17.9) 26 (17.9) 145 (100.0)
1988 58 (50.4) 17 (14.8) 20 (17.4) 20 (17.4) 115 (100.0)
1989 57 (49.1) 33 (28.5) 0 26 (22.4) 116 (100.0)
1990 50 (45.1) 25 (22.5) 24 (21.6) 12 (10.8) 111 (100.0)
1991 34 (36.9) 27 (29.4) 25 (27.2) 6 (6.5) 92 (100.0)
1992 82 (40.8) 58 (28.9) 50 (24.9) 11 (5.5) 201 (100.1)
1993 52 (38.0) 48 (35.0) 21 (15.3) 16 (11.7) 137 (100.0)
1994 20 (23.5) 31 (36.5) 22 (25.9) 12 (14.1) 85 (100.0)
1995 19 (20.9) 33 (36.3) 30 (33.0) 9 (9.9) 91 (100.1)
1996 20 (18.9) 41 (38.7) 27 (25.5) 18 (17.0) 106 (100.1)
1997 21 (17.7) 37 (31.1) 40 (33.6) 21 (17.7) 119 (100.1)
1998 26 (19.1) 37 (27.2) 47 (34.6) 26 (19.1) 136 (100.0)
1999 69 (33.0) 40 (19.1) 59 (28.2) 41 (19.6) 209 (99.9)
Total 913 (41.6) 498 (22.7) 412 (18.8) 372 (17.0) 2,195 (100.1)
Source: Department of Health and Children.
* IDUs = Intravenous drug users.
** Cumulative figure for 1982–5.
TABLE 2.1
Ireland 1985–1999. HIV-Positive C s s by Risk Category.
Numbers and Percentages.
Year IDUs*
n          %
Homosexual
Sex
n          (%)
Heterosexual
Sex / 
Risk Unspecified
n          (%)
Other
n          (%)
TOTAL
n      (%)
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Routine Data on HIV Testing
In Ireland, at the time of writing, the Department of Health and Children, in
collaboration with the Virus Reference Laboratory, based in University College,
Dublin, produces statistics on HIV-positive tests, which are published every six
months. The figures relating to HIV tests are broken down according to risk
category. There are a number of risk categories identified in relation to HIV
infection, including injecting drug use, homosexual sex and haemophiliac
contact. Therefore, it is possible to get a breakdown of the number of positive
HIV cases attributable to injecting drug use in a given year. However, there are
a number of limitations to this data source that should be noted: 
! it is limited to the tested population. Nothing can be inferred for those 
drug users who have not been tested;
! it is not possible to identify non-injecting drug users within the data set;
! no socio-demographic data are collected on those who are tested;
! there is only a limited geographical breakdown available;
! a gender breakdown has only been made available since 1997; and
! both risk behaviours (e.g. injecting drug use) and test locations (e.g. 
prison) are used as categories. This makes the data somewhat unclear. 
For example, it is not known through what risk activity those tested in 
the prison setting became infected with HIV. 
Despite these limitations, this data source provides the best information with
which to examine the epidemiological profile of HIV in Ireland over the past
decade and a half. 
The cumulative figures for the positive cases of HIV from the start of data
collection in 1982 up until 1985, show that just over 60 per cent (n=221) of all
positive cases (n=363) were attributed to injecting drug use (see Table 2.1).  Since
1985, injecting drug use has continued to be one of the main risk categories,
accounting for 41.6 per cent of the cumulative number of positive cases up until
31 December 1999 (see Table 2.1). Two possible explanations have been given by
O'Gorman (1999) for the high proportion of intravenous drug users in the known
HIV-positive population. She argues that the culture of injecting drug use that
existed among drug users in Ireland during the 1980s, at a time when both
information on safe injecting practices and access to clean injecting equipment
were limited,1 resulted in the rapid transmission of HIV among the injecting 
1 The first needle exchange programme in Dublin was established in 1989.
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population. Secondly, she argues, the injecting drug-using population may be
more likely to have been tested for HIV through their contact with drug-
treatment services than those individuals who may be at risk of infection
through other routes, e.g. heterosexual sex (O'Gorman, 1999: 6).
Drug-Related Infectious Diseases
53
The proportion of positive cases attributed to the intravenous drug user category
generally decreased from 1992 through to 1998. In 1994, for the first time,
intravenous drug use accounted for fewer new positive cases than the
'homosexual sex' or 'heterosexual sex/risk unspecified' categories (see Table 2.1).
In fact, the proportion of positive HIV tests attributed to intravenous drug use
fell from 49.1 per cent in 1989, to a low of 17.7 per cent in 1997 (see Table 2.1). It
is suggested that the reduction, both proportionately and in absolute numbers,
over this period may be attributed, at least in part, to the expansion of services
aimed at reducing the spread of HIV among injecting drug users, i.e. substitution
and needle exchange programmes. In an analysis of the trends up until 1998 the
National AIDS Strategy Committee comments that:
Epidemiological surveillance of HIV would indicate that in recent years the
overall incidence of HIV among intravenous drug users is reducing. While we
must be wary of drawing major conclusions from short term changes in
infection patterns service providers are optimistic that this trend is as a result of
the intervention through a combination of substitution therapy with methadone
and needle exchange service (National AIDS Strategy Committee, 2000: 63).
Despite the apparent reduction in the proportion of the total number of positive
cases attributed to injecting drug use, figures from 1999 show a substantial
increase in the number of positive cases attributed to injecting drug use. Between
1998 and 1999 the total number of new cases of HIV increased from 136 to 209.
Furthermore, the number of new positive cases attributed to injecting drug use
increased from 26 of the total new cases (n=136) in 1998, to 69 of the new cases
(n=209) in 1999. Therefore, proportionately, injecting drug use as a risk category
increased from accounting for 19.1 per cent of new HIV-positive cases within this
data source in 1998, to 33 per cent in 1999. This is the highest annual proportion
of new positive cases attributed to injecting drug use since 1993. 
Anecdotal evidence suggests a couple of explanations for the increase in the
number of positive cases attributable to injecting drug use during 1999. Firstly,
leading on from the Protocol for the Prescribing of Methadone, issued by the
Department of Health (1993), guidelines were developed for general
practitioners prescribing methadone within the general-practice setting and for
pharmacists in their dispensing of methadone. Following the completion and
evaluation of a pilot programme, the Report of the Methadone Treatment
Services Review Group made a number of recommendations on tightening
control on both the prescribing and dispensing of methadone, in accordance
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Year Malen %
Female
n %
Total
n %
1997 18 (85.7) 3 (14.3) 21 (100)
1998 16 (61.5) 10 (38.5) 26 (100)
1999 35 (50.7) 34 (49.3) 69 (100)
TABLE 2.2
Ireland 1997–1999. HIV Sero-Positive Intravenous Drug Users by Gender.
Numbers and Percentages.
with the 1993 protocol (Department of Health, 1997). Consequently, the Misuse
of Drugs (Supervision of Prescription and Supply of Methadone) Regulations
were drawn up in 1998. The regulations aim to create a more controlled
environment for the prescribing and dispensing of methadone. Within this
context, all those who were receiving methadone in Ireland were integrated into
a structured programme. Furthermore, drug users were integrated into a
structured programme-setting, where there is an active policy of carrying out
virology (blood test) in relation to HIV and hepatitis. It is suggested that this may
have resulted in an increase in the number of injecting drug users being tested
for HIV and, in turn, an increase in the number of positive cases being attributed
to injecting drug use during 1999. Secondly, it has been suggested anecdotally
that perceptions may be beginning to change among the drug-using population
in relation to HIV. It is argued that the availability of new treatment, i.e. Highly
Active Anti-Retroviral Treatment (HAART), and the visibility of individuals in
the community for whom treatment has been effective, has encouraged people
to come forward for testing so that they can avail of treatment if necessary. 
HIV among Prisoners
As mentioned above, within the Department of Health and Children's reporting
system on HIV-positive tests, those who are tested in prison are categorised
according to the testing location, i.e. prison. Although the proportion of positive
cases from the testing location category of prison which are attributable to
injecting drug use is not known, anecdotal evidence suggests that most of those
being tested have a history of injecting drug use. Since 1989, a total of thirty-nine
new positive cases have been attributed to 'prisoners', thirteen of whom tested
positive in 1999. The use of both risk categories and testing locations in the
Department of Health and Children's reporting system does not allow for any
conclusions to be drawn as to the significance of these figures in relation to the
injecting drug-using population. It is important that the risk category of these
cases be clarified.
HIV and Gender
Gender is the only socio-demographic data collected from those who are tested
for HIV by the Department of Health and Children. Gender has been reported
since 1997. An examination of the figures by gender suggests a possible change
in the profile of those who are testing positive for HIV in Ireland (see Table 2.2).
In 1997, females only accounted for three of the twenty-one new positive cases
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attributed to injecting drug use. In 1998 this had increased to ten of the twenty-
six  positive cases among injecting drug users, and in 1999 it had increased
further to account for thirty-four of the sixty-nine positive cases. Speaking in
percentage terms, women have increased from representing 14.3 per cent of the
positive tests among injecting drug users in 1997, to 38 per cent in 1998, to 49 per
cent in 1999. Owing to the lack of information on gender prior to 1997, it is not
possible to explore trends over a more extended period of time. Anecdotal
evidence suggests that these figures may reflect a real increase in the number of
female,   injecting drug-users who are becoming infected with HIV. However, it
is also suggested that these women may be becoming infected through their
sexual behaviour rather than their injecting drug use. Once identified as an
injecting drug user, however, their infection will tend to be attributed to their
injecting drug-using behaviour. Anecdotal evidence also suggests that a
growing number of women may be attending for testing in order to be able to
minimise the risk of infection to their baby were they to become pregnant.
Source: Department of Health and Children.
Special Studies on HIV Prevalence
A number of special studies have been carried out, which have explored the
prevalence of HIV among cohorts of drug users in a range of study locations. The
studies include drug users located in: the community, drug-treatment centres,
needle exchange programmes and prisons. A summary of the research findings
on the prevalence of HIV infection among particular cohorts of drug users is
presented in Table 2.3 below. 
One of the first studies of drug use in Dublin began in 1985, when O'Kelly &
Bury (1996) identified a cohort of known intravenous drug users in an inner city
area. The prevalence of HIV infection among this group was monitored over the
next decade. In 1991, 57.3 per cent of the total cohort (n=82) were known to be
HIV positive; by 1994, 64.6 per cent of the cohort had tested positive for HIV. In
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Author Study Sample Self Report/ Serum/ Sample % Infected 
Period Source Test Saliva Size of Those 
Teste Tested
Long et al., 1999 Committal Test Saliva IDUs 4 IDUs
(2000) Prisoners (n=173) 5.8%
n=593
Allwright et al., 1998 Irish Prisoners Test Saliva IDUs IDUs
(1999) n= 1,178 (n=509) 3.5%
Smyth et al., 1992- Drug Test Serum IDUs IDUs 
(1998) 1997 Treatment Centre (n=600) 1.2%
n=735
Dorman et. al., 1992 Drug Treatment Test Serum and IDUs IDUs
(1997) Centre & saliva (n=180) 8.4%
Non-Treatment 
n=185
O’Kelly et. al., 1984- IDUs in Test Serum IDUs IDUs
(1996) 1995 community (n=66) 65%
n=82
Johnson et al., 1991 Needle Exchange Test Saliva IDUs IDUs
(1994) (n=81) 14.8%
total, eighteen of those who had tested positive by 1994 had died. O'Kelly & Bury
(1996) argue that the high prevalence rate of HIV among this cohort reflects the
context in which their intravenous drug use developed. They argue that 'the
uncontrolled use of injected drugs and the sharing of scarce equipment were
commonplace at the time; the true impact of these practices is now clear in terms
of the spread of HIV infection among the young people who lived there' (O'Kelly
& Bury, 1996: 114). Another study, carried out in Dublin with a cohort who had
begun injecting during the same period, found similar rates of HIV prevalence.
Williams, Mullan, O'Connor & Kinsella (1990) found that, of a cohort of sixty-
nine individuals on a methadone maintenance programme, 70 per cent were
HIV positive.
These high prevalence rates of HIV were not found in the Dublin-based studies
subsequent to those of O'Kelly & Bury (1996) and Williams et al. (1990). Johnson
et al. (1994) found that in 1991, 14.8 per cent of a sample recruited from a needle
exchange programme were HIV positive. The Dorman, Keenan, Schuttler, Merry
& O'Connor (1997) study, carried out in 1992 in the context of a World Health
Organisation multi-national research initiative, found that 8.4 per cent of a
sample of 180 injecting drug users, recruited from both in and out of treatment,
were HIV positive. In contrast, the Smyth, Keenan & O'Connor (1998) study of a
drug-treatment sample, tested between 1992 and 1997, found a prevalence rate
for HIV of only 1.2 per cent. This is low in contrast to an estimated 8 per cent
prevalence rate (based on laboratory reports) among injectors attending Eastern
Health Board methadone clinics in 1997 (Barry, cited in Allwright, Barry,
Bradley, Long & Thornton, 1999: 2).
More recently, two studies have been carried, reporting on HIV prevalence
among the Irish prison population (Allwright et al., 1999; Long et al., 2000).
Included in the data are the prevalence rates for those prisoners who have a
history of injecting drug use. It was found that 5.8 per cent of committal
prisoners2 (Long et al., 2000) and 3.5 per cent of general prisoners3 (Allwright
et al., 1999) with a history of injecting drug use were HIV positive. Among those
prisoners who reported no history of injecting drug use, the infection rates were
0.5 per cent among the committal population (Long et al., 2000) and 0.9 per cent
within the general prison population (Allwright et al., 1999). In an environment
where injecting drug use is on-going, and in the absence of any provision for
clean injecting equipment, the risk for the spread of infection within this
population is high. 
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TABLE 2.4
Ireland 1998-2000. Summa y of R search Findi gs on the Prevalence of Hepatitis
B Infection among Particular Cohorts of Drug Users.
Numbers and Percentages.
Author
Long et al., (2000) 1999
Committal Prisoners
n=593
Test Saliva
IDUs
(n=173)
IDUs
17.9%
Allwright et al., (1999) 1998
Irish Prison Population
n=1,178
Test Saliva
IDUs
(n=509)
IDUs
18.5%
Smyth et al., (1998)
1992-
1997
Drug Treatment Centre
n=735
Test Serum
IDUs
(n=729)
IDUs
1%
Study
Period
Sample Source
Self
Report
Test
Serum/S
aliva
Sample
Size
Tested
%Infec
ted of
Those
Tested
IDUs = Intravenous drug users.
In summary, injecting drug use continues to be one of the main risk categories to
which HIV-positive cases are attributed each year. Despite the rate of new HIV-
positive cases attributed to injecting drug use plateauing in the early and mid-
1990s, recent figures suggest that there is an upward trend in the number of new
HIV-positive cases among Irish drug users. The information available on those
testing positive for HIV remains limited. Analysis of the figures highlights the
need for more information, in particular of a socio-demographic and behavioural
nature, to facilitate comprehensive epidemiological analysis of the trends.
Table 2.3. Ireland 1994-1999. Summary of Research Findings on the
Prevalence of HIV Infection among Particular Cohorts of Drug Users.
2 'Committal prisoners are prisoners who have been admitted to the prison within the preceding 48 hours,
accused or guilty of a new crime, excluding those on temporary release or transferred from another prison. The
committal population includes individuals entering on remand, following sentence, committed as a result of a
bench warrant and non-nationals without valid documentation' (Long et al., 2000: 2).
A Collection of Papers on Drug Issues in Ireland
58
3 All those incarcerated irrespective of their committal status.
4 IDUs: Injecting drug users
2.2.2  Hepatitis B
There is very little information in Ireland on the prevalence and incidence of
hepatitis B among both the general population and the injecting drug-using
population. While data are collected on the number of positive tests carried out
for hepatitis B by the Virus Reference Laboratory, no behavioural data are
collected and, therefore, those infected through drug use cannot be identified.
Information on prevalence rates is thus confined to a small number of special
studies that have been carried out in the field. 
The Smyth et al. (1998) study of drug users located in a treatment setting found
that only 1 per cent were infected with hepatitis B. However, more recent
research carried out in the prison setting found significantly higher prevalence
rates among injecting drug users. Allwright et al. (1999) and Long et al. (2000)
found 18.5 per cent and 17.9 per cent prevalence rates for hepatitis B,
respectively. While these figures suggest that hepatitis B may be prevalent
among the injecting drug-user population, the lack of data prohibits any in-
depth epidemiological analysis of the situation in Ireland.
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TABLE 2.5
Ireland 1995-2000 Summary of Research Findings on the Prevalence of
Hepatitis C Infection among Particula  C horts of Drug Users.
Numbers and Percentages.
Author
Long et al., (2000) 1999
Committal Prisoners
n=593
Test Serum
IDUs
(n=173)
Non
IDUs
(n=420)
IDUs
71.7%
Non
IDUs
1.4%
Allwright et al., (1999) 1998
Irish Prison Population
n=1,178
Test Serum
IDUs
(n=509)
Non
IDUs
(n=669)
IDUs
81.3%
Non
IDUs
3.7%
Smyth et al., (1998)
1993-
1996
Drug Treatment Centre
n=353
Test Serum IDUs(n=353)
IDUs
52.1%
Smyth et al., (1999b) 1997
Drug Treatment Centre
n=84
Self-
report
n/a IDUs(n=84)
IDUs
89%
Smyth et al., (1998)
1992-
1997
Drug Treatment Centre
n=735
Test Serum IDUs(n=733)
IDUs
61.8%
Smyth et al., (1995)
1992-
1993
Drug Treatment Centre
n=272
Test Serum IDUs(n=272)
IDUs
84%
Test-
ing
Period
Sample Source
Self
Report
Test
Serum/
Saliva
Sample
Size
Tested
%Infec-
ted of
Those
Tested
IDUs = Intravenous drug users.
2.2.3  Hepatitis C
In Ireland, there is no routine data collection in the area of hepatitis C. However,
there have been a number of special studies carried out among samples of drug
users in a variety of study settings (see Table 2.5). 
The first study of hepatitis C infection among injecting drug-users was carried
out between August 1992 and August 1993 by Smyth, Keenan, Dorman &
O'Connor  (1995). The study sample was identified through a treatment centre,
where all new attenders and re-attenders who presented during the study period
and who reported a history of injecting drug use were encouraged to take part.
In total, 272 injecting drug-users took part and a prevalence rate of 84 per cent
for infection with hepatitis C was found. Among those injectors who had been
injecting for between six months and two years inclusive, the prevalence rate
was 70 per cent. Among those with an injecting history of longer than two years,
the prevalence rate was 95 per cent. Furthermore, there was a significant gender
difference in relation to infection: of the 194 males, 156  (80%) tested positive,
whereas 73 of the 78 females (94%) were positive. 
Further studies were carried out by Smyth et al. (1998) and Smyth, Keenan &
O'Connor (1999a), which examined the prevalence of hepatitis C infection
among in-treatment populations. Consecutive new attenders at a treatment
service, who attended between July 1993 and December 1996, were approached
to take part in the study. In all, a sample of 353 injecting drug-users who
reported an injecting history of less than twenty-five months were recruited.
Overall, a prevalence rate of 52.1 per cent was recorded in this sample. In an
extension of this study cohort, Smyth et al. (1998) later found that of 733
consecutive new attenders between September 1992 and September 1997 at the
same treatment centre, 61.8 per cent were hepatitis C positive.
In two prison studies, which have been discussed in previous sections, the
prevalence of hepatitis C among prisoners was explored (Allwright et al., 1999;
Long et al., 2000). The prevalence of hepatitis C infection was found to be high
within this population. Allwright et al. (1999) found that among 509 prisoners
with a history of injecting drug use, 81.3 per cent tested positive for hepatitis C.
In contrast, only 3.7 per cent of those prisoners who did not report a history of
injecting drug use had tested positive for hepatitis C. A follow-up study of the
committal prisoner population (Long et al., 2000) found that, of 173 prisoners
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with a history of injecting drug use, 71.7 per cent were hepatitis C positive. Only
1.4 per cent of those prisoners who reported that they had no history of injecting
drug use tested positive for hepatitis C. 
While it is not possible from the available data to analyse infection trends over
time, it would appear from the studies available that hepatitis C infection has
been prevalent among Irish injecting drug-users over the past decade. Anecdotal
evidence suggests that the relative ease with which hepatitis C can be spread
through injecting drug use, and a lack of knowledge among users about hepatitis
C and the associated risks, have all contributed to its spread. In summary, the
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prevalence rate for hepatitis C infection has been found to be consistently high
within the drug-using population over the past decade.
2.2.4  Summary
The most comprehensive data available on drug-related infectious diseases in
Ireland are for HIV. While the number of new, positive tested cases for HIV,
which were attributable to injecting drug use, appeared to stabilise in the mid-
1990s, figures for 1999 show an increase in the number of cases. For both
hepatitis B and C, analysis is dependent solely on data from special studies.
Despite the absence of comprehensive data it appears from the evidence
available that hepatitis C continues to be highly prevalent among Irish injecting
drug users. Overall, it would appear from the data available that drug-related
infectious diseases continue to be a concern in relation to Irish injecting drug
users. Furthermore, this highlights the need for more comprehensive data
collection in the area of all drug-related infectious diseases in order to monitor
changes in the trends over time.
2. 3  Determinants of Drug-Related Infectious Diseases
This section addresses some of the determinants of drug-related infectious
diseases in the Irish context. It examines research that has looked at the risk
behaviours engaged in by Irish drug users, both in relation to their injecting drug
use and their sexual behaviour. Furthermore, it explores the data available on
both the health-related consequences and the wider social consequences of drug-
related infectious diseases.
2.3.1 Injecting Risk Behaviour
Once the link between the spread of HIV and injecting drug use was established
in the mid-1980s, the risk behaviours engaged in by the injecting drug-using
population became a focus of research. In the Irish context, studies on the
injecting risk behaviour of drug users have spanned the last decade. During this
period the provision of harm-reduction strategies has expanded from being
available through a small number of programmes to a small number of drug
users, to more widespread availability, to a significant number of programmes
catering for a significant number of drug users. This section first describes the
findings of research related to the risk behaviours of the general injecting
population, and then second describes the findings relating to three sub-groups
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of particular interest - young injectors, female injectors and injecting drug users
in prison. 
Injecting Drug Users in General 
Research carried out by Johnson et al. (1994) in 1991, among a sample of
attendees at a Dublin needle exchange, found that 52.6 per cent of respondents
reported that they had not shared equipment during the preceding twenty-eight
days, while over 34.2 per cent had shared with two or more other people. A
study carried out a year later, in 1992 (Dorman et al., 1997), among a sample
(n=185) of injecting drug users both in and out of treatment, found that 55.7 per
cent of the sample had shared and 61.6 per cent had lent injecting equipment in
the previous six months. 
Despite the expansion of harm-reduction strategies since the two studies
described above (Johnson et al., 1994; Dorman et al., 1997) were carried out, more
recent research has found that Irish drug users continue to engage in risky
injecting behaviour. In a study of those attending a needle exchange programme,
Cox & Lawless (2000) found that 59 per cent of the sample who had a history of
injecting drug use (n=1,323) reported sharing injecting equipment at some stage
in their injecting drug-using career. Furthermore, 29 per cent of these
respondents reported sharing recently (i.e. in the previous four weeks). Among
the 29 per cent who reported sharing recently, 17 per cent had lent their injecting
equipment, 50 per cent had borrowed it and 33 per cent had done both. Data
from the National Drug Treatment Reporting System (NDTRS), operated by the
Drug Misuse Research Division of the Health Research Board, offers further
evidence that Irish drug users continue to engage in injecting risk behaviours. In
1998, 575 out of first-treatment contacts (n=1,625) reported that they had ever
injected a drug, and 45.6 per cent of these reported that they had ever shared
injecting equipment. Furthermore, 352 of this sample reported that they were
currently injecting (i.e. within the last month), and 26 per cent (n=94) of these
reported that they were currently sharing injecting equipment (i.e. within the
last month).
Young Injectors 
In a study specifically aimed at exploring the risk behaviours engaged in by a
sample of young injectors (n=485), i.e. those under the age of 25, Cassin,
Geoghegan & Cox (1998) found a significant proportion regularly engaged in
injecting risk behaviours. Compared with a cohort of older injectors (n=285), i.e.
those over the age of 25, who were attending the same service, younger clients
were found to be significantly more likely to have reported both lending and
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borrowing used needles and syringes in the four weeks prior to first contact with
the syringe exchange programme. Furthermore, 64.3 per cent of the younger
cohort reported that they had shared injecting paraphernalia (i.e. spoons and
filters) in the four weeks prior to contacting the service, compared to only 43.8
per cent of the older cohort. 
Female Injectors 
Female drug users have been studied specifically in relation to their injecting risk
behaviours. Cox & Lawless (2000) found that among a cohort of needle-exchange
clients, women (n=304) were significantly more likely than men (n=1,000) to
report sharing injecting equipment with their sexual partner and to share
injecting paraphernalia with other injecting drug users. While 53 per cent of men
reported that they had shared injecting paraphernalia, 63 per cent of females
reported that they did so. The gender difference was more acute in relation to
sharing injecting equipment with a sexual partner: 13 per cent of men compared
to 37 per cent of women reported that they did so. However, this was directly
related to the fact that 68 per cent of women reported that they had a sexual
partner who was an injecting drug user, compared to just 24 per cent of men. Cox
& Lawless (2000) argue that the greater personal involvement of women with
other drug users has consequences in terms of health-related problems and risk
behaviour. The social opportunities created by living in close proximity with
other injecting drug users creates an environment in which risk behaviour
flourishes (Cox & Lawless, 2000). 
Injecting Drug Users in Prison 
To date, Irish prisoners do not have access to clean injecting equipment and only
a very limited number have access to a methadone maintenance programme in
the prison setting. This implies that, where injecting drug use occurs in the
prison, it may be particularly risky in relation to the spread of drug-related
infectious diseases. 
O'Mahony's (1997) study in a Dublin prison found that 42 per cent (n=45) of a
sample of 108 prisoners had used heroin while in prison serving their current
sentence. Of these forty-five, thirty-seven had engaged in intravenous use. One-
sixth of those reporting a history of drug use had tested positive for HIV, while
a quarter had never been tested. In addition, half these drug users said they had
tested positive for at least one form of hepatitis. O'Mahony described as
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'alarming' (O'Mahony, 1997: 107) the finding that, of those who reported having
tested positive for HIV, 60 per cent had engaged in needle sharing since being
notified of their positive status. An earlier study, based on data gathered
between 1987 and 1991, found that during this period, 168 known HIV-positive
prisoners had spent time in Mountjoy Prison in Dublin. A study of a sub-sample
of these HIV-positive individuals, selected on a random basis, found that 94 per
cent had engaged in drug use within the prison, suggesting a potential spread of
HIV to uninfected prisoners (Murphy, Gaffney, Carey, Dooley & Mulcahy, 1992). 
A more recent study of HIV and hepatitis B/C prevalence among prisoners
investigated the sharing of injecting equipment in the prison setting (Allwright
et al., 1999).  As may be expected in an environment where there is no formal
access to injecting equipment, it was found that injecting drug users were more
likely to share injecting equipment while in prison than when they were in the
community. Of injecting drug users, 58 per cent reported that they had shared
all injecting equipment (i.e. needles, syringes, filters, spoons) while in prison,
compared to 37 per cent who reported sharing in the month prior to being
incarcerated. Furthermore, of those injecting drug users who had shared
injecting equipment inside the prison, 89.1 per cent had tested positive for
hepatitis C. 
2.3.2  Sexual Risk Behaviour
In 1985 Irish family planning legislation was amended to allow for the sale of
condoms to people over the age of 18 without a prescription from a range of
named outlets. The sale of condoms was not deregulated in Ireland until 1993,
when the law was changed to make condoms available for sale through outlets
other than pharmacies. This change in the law was principally in response to
public health concerns in relation to HIV/AIDS, and the law referred to
condoms as infection preventers rather than as pregnancy preventers
(Prendiville & Smith,  1993). Condoms are sold from a wide range of sources,
including vending machines. Furthermore, condoms are distributed freely to
groups considered to be at high risk of infection, including injecting drug users.
Despite the wide availability of condoms, research carried out among drug users
suggests that they continue to engage in sexual risk behaviours which may
facilitate the spread of HIV and other infectious diseases. 
A study of first-time attenders at the Eastern Regional Health Authority needle
exchange programmes from 1990 to 1997 found that only 55 per cent of first-time
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attenders (n=5,152) reported using a condom during sexual encounters in the
previous year (Mullen & Barry, 1998). A study of drug-using women working in
prostitution (n=77) (O'Neill & O'Connor, 1999), 83 per cent of whom reported
injecting drugs in the previous month, found that while 92 per cent 'always' used
condoms with clients for vaginal sex, only 15 per cent 'always' used condoms
with their partners for vaginal sex. Furthermore, while none reported 'never'
using condoms with clients for vaginal sex, 52 per cent reported that they 'never'
used condoms with partners for vaginal sex. There were similar findings in
research carried out with a cohort of clients attending a syringe exchange
programme (n=1,309). It was found that 25 per cent of those who reported
having no regular sexual partner reported 'never' using condoms, whereas 41
per cent of clients who reported having a regular sexual partner (n=865) reported
'never' using condoms. It has been argued that the reluctance to use condoms
within long-term or steady sexual relationships can be particularly problematic;
this has been argued both in the context of the drug-using population (Cox &
Lawless, 2000) and the general population (Mahon, Conlon & Dillon, 1998). 
2.3.3  Summary
In summary, this section highlights the extent to which Irish drug users continue
to engage in behaviours conducive to the spread of drug-related infectious
diseases, both through their injecting drug use and their sexual activity. Despite
the expansion of harm-reduction strategies since the early 1990s, Irish drug-users
continue to engage in these risk behaviours. The findings of studies carried out
in the early 1990s in relation to risk behaviours may be explained by a lack of
appropriate service provision and a lack of knowledge among both service
providers and users of the risks involved in sharing. However, the more recent
study findings show that these patterns of risk behaviour continue to exist
despite the presence of appropriate services. Section 2.5 presents the research
findings on whether the introduction of harm-reduction strategies have had an
impact on drug users' risk behaviours.
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Intravenous Drug Use
Related* 142 61 43 21 22 27 25 27 34 17 10 1 12 8 16 7
Homo/Bisexual
Haemophiliacs/ 109 45 13 14 27 11 16 11 34 16 12 3 13 9 13 5
Heterosexuals
Others 52 27 12 9 18 6 13 8 11 1 8 2 14 4 11 5
Undetermined 5 3 0 0 0 0 1 0 0 0 2 1 2 0 1 0
Total 308 136 68 44 67 44 55 46 79 34 32 7 41 21 41 17
Risk Category 1982-1992
Cases Deaths
1993
Cases Deaths
1994
Cases Deaths
1995
Cases Deaths
1996
Cases Deaths
1997
Cases Deaths
1998
Cases Deaths
1999
Cases Deaths
TABLE 2.6
Ireland 1982-1999. AIDS Cases and Deaths by Risk Category.
Numbers
Source: Department of Health and Children / Virus Reference Laboratory.
*Includes categories ‘intravenous drug users’, ‘homo-bisexual/intravenous drug users’ and ‘babies born to intravenous drug users’.
D
rug-R
elated
 Infectious D
iseases
2.4  Consequences of Drug-Related Infectious Diseases
The consequences of drug-related infectious diseases have not received
significant attention in the Irish literature. This chapter explores the data
available on both the health-related consequences and the wider social
consequences of drug-related infectious diseases.
2.4.1  Health-Related Consequences
The most obvious consequences of HIV and hepatitis B and C infection are the
impact these diseases have on the individual's health. There are no data available
on the number of drug users who develop chronic hepatitis C infection or
require care for hepatitis B infection. The only data collected on the health
consequences of drug-related infectious diseases are those on AIDS-related cases
and deaths. Since recording began in 1982 and up until 31 December  1999, there
have been 691 AIDS cases reported in Ireland, and 349 AIDS-related deaths (see
Table 2.6). In 1999 there were 41 new AIDS-related cases recorded. Intravenous
drug users continue to represent one of the main risk categories recorded in this
data source. In 1999 intravenous drug users accounted for 39 per cent of new
AIDS cases, and 41 per cent of the year's AIDS-related deaths. 
Another area of concern is the extent to which HIV/AIDS is passed on from
mother to baby. From January 1986 to December 1999, a total of 172 HIV-positive
cases were attributed to the category 'children at risk', representing 7.84 per cent
of the total HIV-positive cases reported over the period (Department of Health
and Children). However, this category does not indicate the route of infection
and it is therefore not known to what extent HIV among these children is
attributable to maternal injecting drug use. However, the statistics collected on
AIDS cases and deaths indicate where a child's infection is attributable to
maternal drug use. In total, from 1982 to 1999 fourteen children born to drug
users were recorded as AIDS cases; this represents 2 per cent of the total 691
cases recorded up to 31 December 1999. Furthermore, there were eight AIDS-
related deaths among children of injecting drug users recorded in the same time
period, which accounts for 2.3 per cent of the total 349 deaths recorded up to 31
December 1999.
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In summary, little is known about the health-related consequences of drug-
related infectious diseases in Ireland. While there have been improvements in
treatment procedures, particularly in the area of HIV, coping with the impact of
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the high prevalence rate of hepatitis C infection will present a particular
challenge to service providers.
2.4.2  Social Consequences
The close link between social deprivation and problematic drug use in Ireland
has meant that those affected by drug-related infectious diseases are generally
from areas characterised by high levels of social deprivation. Individuals who
may be considered socially excluded may therefore suffer further exclusion as a
result of being affected by a drug-related infectious disease. In this context, it is
important that the wider social consequences of drug-related infectious diseases
be considered. However, little research has been carried out in this field, either
on individuals infected, their families or the community at large. 
As part of a wider study on heroin use in Dublin's inner city, McCarthy &
McCarthy (1997) surveyed twenty-six opiate users and eighteen families in
which there was a drug-using member. Among both groups, drug-related
infectious diseases were raised as an issue of concern. A number of respondents
reported that they had to cope with either their own or a family member's
infection and its effects. Particularly acute were the concerns expressed by
individuals in families where another member was HIV positive. Twenty-eight
of the respondents from the family cohort reported that they had a family
member who was HIV positive or living with AIDS. One mother reported that
four of her children had died from AIDS-related illnesses between 1989 and 1995
(McCarthy & McCarthy, 1997: 58). It was also found, however, that none of the
respondents who lived with a person who was infected with HIV had availed of
any formal support services for themselves in relation to HIV/AIDS issues.
O'Gorman (1999) carried out a qualitative study of the experiences of both
people directly infected by HIV and also those whose lives were affected by HIV,
i.e. the parents, partners, children and siblings of people who were HIV positive.
In total, members of nineteen families participated in the study - twenty-six
adults and seven children who had been diagnosed HIV positive, and a further
twenty-nine adults and fifty-four children who were affected by HIV/AIDS.
This study highlights the complex nature of the problems faced by both those
infected with and those affected by HIV/AIDS. The problems identified include
the trauma involved in being diagnosed; informing other family members (e.g.
partners, children), who may be at risk of infection; caring for a child who is HIV
positive, when the parent is also HIV positive; complying with treatment
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regimes; and coping with an AIDS-related death. O'Gorman (1999) argues that
in the absence of adequate public information campaigns, HIV and AIDS
continue to be widely viewed within Irish society with 'prejudice, fear and
ignorance' (O'Gorman, 1999: 55). Consequently, those infected with the disease
and their families have to live with the added strain of coping with the stigma
and secrecy that surrounds HIV. 
In summary, as in other European countries, the consequences of drug-related
diseases in Ireland are multi-faceted. While they encompass consequences on the
health and general well-being of the infected individual, they also impact on the
infected individual's family and wider community. The wider social
consequences of drug-related infectious diseases have been largely neglected in
the Irish context and are in need of further attention.
2.5  New Developments and Uptake of Prevention/Harm
Reduction and Care
As mentioned in previous sections, harm-reduction strategies play a key role in
the provision of services for drug users in Ireland. Both needle exchange
programmes and those based on substitution treatment were expanded in an
attempt to curb the spread of HIV among injecting drug users. More recently,
there has been an increased focus on the role these services play in preventing
the spread of other drug-related infectious diseases, i.e. hepatitis B and C. This
section gives an overview of the harm-reduction services available to Irish
injecting drug users, which aim to prevent the spread of drug-related infectious
diseases among this population. Furthermore, the section gives a brief overview
of those services that provide care for those already infected. The following areas
of service  provision will be addressed:
2.5.1 Harm Reduction Programmes 
2.5.2 Testing and Treatment
2.5.3 Hepatitis C Vaccination
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2.5.1  Harm Reduction Programmes
A number of harm-reduction strategies have been developed, which specifically
aim to prevent the spread of HIV and other drug-related infectious diseases
among injecting drug users in Ireland. However, the impact of these
programmes on infection rates among injecting drug users are unclear. Smyth et
al. (1999a) attempted to explore the impact of these programmes on the spread
of hepatitis C by carrying out tests for hepatitis C among a cohort of drug users.
The cohort included those who had begun their injecting drug use before and
after the expansion of harm-reduction programmes in Ireland. Smyth et al.
(1999a) argue that the findings suggest that those injecting drug users who began
their injecting drug use after the introduction of harm-reduction strategies,
demonstrated a reduced risk of hepatitis C infection. However, Smyth et al.
(1999a) emphasise that it was not possible to control for other factors that may
explain the decline in the hepatitis C infection rate, such as a possible reduction
in overall injecting frequency among more recent injectors. 
In this section three specific harm reduction services will be briefly overviewed,
and any research findings in relation to the impact they may have had on the
spread of drug-related infectious diseases presented. The services that will be
covered in this section are:
! Information and Education Programmes
! Needle Exchange Programmes 
! Substitution Programmes
Information and Education Programmes
Information on drug-related infectious diseases is made available to drug users
through a number of sources. Leaflets containing information on what these
diseases are and how they are spread are available to drug users from a number
of locations, including drug treatment centres, health centres, drop-in centres
and voluntary organisations. An information booklet dealing specifically with
hepatitis C has recently been produced, which is directly aimed at informing
drug users and their families about the disease (Keating, 2000). Furthermore,
there have been a limited number of education programmes aimed at informing
drug users directly about drug-related infectious diseases and the associated
risks. In 1996 the Health Promotion Unit of the Department of Health and
Children produced guidelines for effective HIV/AIDS education (Department of
Health, 1996). An example of an education programme aimed directly at drug
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users was established by the Probation and Welfare Service in Mountjoy Prison,
Dublin. This Drug Awareness Programme is a four-week programme consisting
of one session per week. The principal aim is to educate participants about their
drug use and the associated risks. It is aimed at all prisoners with a history of
drug use, including those who have ceased their drug use and those who are
continuing to use in the prison setting. Included in this programme is a session
on HIV and hepatitis. 
While education and dissemination of information about drug-related infectious
diseases and the associated risks have been an important component in Ireland's
prevention strategy, the effectiveness of information dissemination and the
impact of such information on risk behaviour is unclear. Prior to the
development of the Probation and Welfare Service's Drug Awareness
Programme in Mountjoy Prison, an award-winning booklet and video,
containing information for prisoners on HIV discrimination, infection and
prevention, were produced and were supposedly available to all prisoners.
However, a study carried out, based on focus-group interviews with prisoners
and former prisoners, found that HIV-positive individuals in the focus groups
had seen neither of these materials (O'Brien & Stevens, 1997). Furthermore, as
will be discussed in more detail below, Smyth et al. (1999b) found that even
where injecting drug users may be attending a treatment service and may have
regular contact with health professionals, this does not necessarily result in the
drug user developing a better understanding of hepatitis C and the related risk
behaviours. Bourke (1998) also found that, in a cohort (n=66) of young injecting
heroin users (aged 15 to 22 years) attending services, 'whilst most understood the
significance of sharing needles few were aware that sharing barrels, spoons and
filters put them at risk' (Bourke, 1998: 4).
It would appear from the evidence available that information is not always
passed on to injecting drug users in an effective manner. Despite the existence of
education and information materials as part of the prevention strategy in the
area of drug-related infectious diseases, it would appear that there is a need for
this information and education to be delivered in a more effective manner. 
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Needle Exchange Programmes
The first needle exchange programme in Ireland was established in 1989. Since
then the service has been expanded to include approximately twelve sites. All
the sites are located in the Eastern Regional Health Authority (ERHA) area,5
which includes Dublin City and surrounding areas. Three types of programmes
exist:
! The Merchant's Quay Project is a voluntary organisation, which, among 
other services, provides a needle exchange programme.
! A mobile clinic, which provides low-threshold services to drug users, 
including a needle exchange and a low dosage methadone programme. 
This clinic services four areas in Dublin City and the surrounding 
suburbs on a Monday to Friday basis.
! The remaining programmes are all in statutory services run by the 
ERHA. These are located in health centres and drug-treatment centres 
around the city. 
A one-for-one exchange of needles is aimed for by all needle exchange services.
However, there is flexibility in order to ensure the service is client-friendly. The
mean number of needles given out to injecting drug users at first attendance at
ERHA exchange programmes is 4.0 (Mullen & Barry, 1998). Overall, the ERHA
programmes estimate that approximately 60-70 per cent of needles are returned
to its exchange programmes. For 'first-time' clients at the Merchant's Quay
Project, the number of syringes and needles given is normally two barrels and
six needles (or six microfines) (Cox & Lawless, 2000). In 1998 a total of 16,509
syringes were dispensed by the Merchant's Quay Project through its exchange
programme (Cox & Lawless, 2000). 
While there has been an expansion in the number of needle exchange
programmes available to Irish drug users, a need for further expansion has been
identified. An external review of drug services in the Eastern Health Board
(EHB) area,  has described needle exchange provision in Dublin as 'patchy and
not very comprehensive' (Farrell, Gerarda & Marsden, 2000: 13). While it is
recognised that community resistance may impact on the expansion of these
services, it is argued that there needs to be a wider geographical distribution of
these services. Pharmacies have been suggested as a potential source for clean
injecting equipment for injecting drug users. 
5 Formerly the Eastern Health Board (EHB).
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While there are no restrictions on pharmacies in relation to selling injecting
equipment in Ireland, anecdotal evidence suggests that, in practice, this rarely
happens. Currently there is no central policy or programme under which
pharmacists provide needles to injecting drug users. The Pharmaceutical Society
of Ireland has stated that it supports 'the principle of needle and syringe
exchange. Its members are ready and willing to provide such a service as part of
a comprehensive national needle and syringe exchange network' (McDermott,
1999). 
In an evaluation of the Merchant's Quay Project's syringe exchange programme,
it was found that it had had a positive impact on reducing the incidence of
injecting risk behaviours among clients. Clients were questioned about their risk
behaviour when they first attended the service and then again after three
months. Within this period it was found that there was a 76 per cent reduction
in the numbers reporting lending injecting equipment and a 71 per cent
reduction in the numbers reporting borrowing injecting equipment (Cox &
Lawless, 2000: 69).
Substitution Programmes
Substitution programmes currently account for the majority of treatment
programmes available to injecting drug users in Ireland. At the end of August
2000 there were 4,813 clients receiving substitution treatment in Ireland. The
service is provided in a range of settings including addiction centres, satellite
clinics and from general practitioners in their own surgeries. It is assumed that
by providing a substitute opiate (i.e. methadone), and monitoring illicit drug use
through urinalysis, participation on a substitution programme will reduce the
illicit opiate intake of a client and, in turn, their injecting drug use. However, a
secondary function of substitution programmes in relation to preventing the
spread of drug-related infectious diseases is the dissemination of information to
clients about HIV and hepatitis and associated risk behaviour. 
Williams et al. (1990) carried out a study with sixty-nine clients of a methadone
maintenance treatment programme to investigate the extent of 'at-risk'
behaviour for HIV transmission among those known to be sero-positive, and to
measure the degree of positive change in their risk behaviour. It is important to
note that this study was carried out in 1988, prior to the introduction of needle
exchange programmes by the health board. Of those who were HIV positive
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(n=48), 63 per cent admitted that they had continued to share injecting
equipment since getting a positive test result. However, when comparing their
reported pre-test activities, the findings were deemed to be encouraging. Prior to
being tested, 98 per cent  reported that they had shared injecting equipment,
compared to 63 per cent after testing.
More recently, in 1997, Smyth et al. (1999b) carried out a study of knowledge
regarding hepatitis C among a sample of injecting drug users (n=84) in a
treatment setting in Dublin. Included in the sample were individuals who were
on a methadone maintenance programme and those who were on a short-term
detoxification programme. The researchers' basic hypothesis was that those
injecting drug users with increased contact with medical services would
demonstrate better understanding of hepatitis C and associated risk behaviours,
i.e. a 'dose-response' type effect. This hypothesis was not confirmed. Seventy-
three of the sample recognised the four main infection routes, i.e. injecting drug
use, sex, transfusion and vertical. However, only 44 per cent recognised activities
with no associated risk, i.e. injecting without sharing, smoking heroin, and
kissing. Smyth et al. (1999b) express concern about the finding that substantial
minorities believe that there is a risk of exposure even when not sharing injecting
paraphernalia. They argue that perceived personal vulnerability to infections
such as hepatitis C is likely to be a factor in leading individuals to avoid
practising unsafe injecting behaviour. Where this vulnerability is diminished by
false beliefs about already having been exposed to infection, when actually
engaging in 'safe' practices, then the preparedness to share injecting equipment
may well increase. 
In summary, while section 2.2 showed that a significant proportion of Irish
injecting drug users continue to engage in injecting risk behaviours, it would
appear from this section that harm-reduction strategies have had some positive
impact on injecting drug users' risk behaviours. While there is a need to improve
the delivery of some services, the findings suggest that infection rates would be
higher in the absence of the current harm reduction strategies.
2.5.2  Testing and Treatment 
Testing
Testing for hepatitis and HIV is offered to all those entering treatment and is
encouraged by low-threshold services such as needle exchange programmes. In
A Collection of Papers on Drug Issues in Ireland
76
these settings clients are given test results and may be offered referral to
treatment where appropriate. The actual proportion of injecting drug users who
have been tested for either hepatitis or HIV remains unknown. A study of HIV
and hepatitis B and C prevalence among the prison population (Allwright et al.,
1999) found that of 509 prisoners with a history of injecting drug use, 59.3 per
cent reported that they had been tested for hepatitis C, 49.6 per cent for hepatitis
B and 65 per cent for HIV. In the Cox & Lawless (2000) study of needle exchange
attenders, 49 per cent reported that they had been tested for HIV. It has also been
found that young injecting drug users (below the age of 25) are significantly less
likely to have been tested for either HIV or hepatitis than the older cohort
(Cassin et al., 1998). While the specific nature of these study populations needs
to be considered, these figures suggest that a significant proportion of drug users
have not been tested for the various drug-related infectious diseases.
Treatment
The provision of treatment for those infected with both HIV and hepatitis C is a
key aspect of drug-related infectious diseases. Treatment programmes for both
HIV and hepatitis C are available free of charge in Ireland. While it is not
essential for drug users to be referred by drug treatment clinics for HIV and
hepatitis C treatment, this is the route generally followed.
Highly Active Anti-Retroviral Treatment (HAART) is available free of charge to
drug users through referral to genito-urinary medicine (GUM) and infectious-
disease clinics in Ireland. There are four clinics that provide HAART, three based
in Dublin, the fourth in southern Ireland in Cork. The selection of patients for
HAART is based on internationally-recommended medical criteria, and the
motivation of the individual to undergo the treatment. A drug user generally has
to be stable on a substitution programme before he/she will be accepted on to a
HAART programme. This is due to problems of compliance with the treatment
regime and concerns about the risks of prescribing HAART to those who are
continuing to engage in illicit drug use.
Treatment for hepatitis C is also available to drug users where its provision is
deemed appropriate. Guidelines have been developed for selecting suitable
candidates for hepatitis C treatment. It is generally agreed among service
providers that a potential client should be 'drug stable' (i.e. free from street
opiates and injecting drug use) for a minimum of a year prior to starting
treatment and that they should not be drinking alcohol (Keating, 2000). As with
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HAART, it is argued that an individual needs to be drug stable in order to
maximise the chances of compliance with the treatment regime involved for
hepatitis C. Therefore, while a person with a history of injecting drug use may
access treatment for hepatitis C, an active injecting drug user may not. 
2.5.3  Hepatitis B Vaccination
Hepatitis B vaccination is available free of charge to all injecting drug users
through the drug services and, where the individual is entitled to free medical
care, through their general practitioner. However, anecdotal evidence suggests
there is a lack of knowledge among drug users about hepatitis B in general, and
about the availability of a vaccination. Furthermore, anecdotal evidence suggests
that not all service providers are offering drug users the hepatitis B vaccination.
While the total proportion of injecting drug users who are vaccinated against
hepatitis B is not known, special studies have found that a relatively low
proportion report having received a vaccination. A study of those clients
attending the Merchant's Quay Project found that only 19 per cent of clients
reported having been vaccinated for hepatitis B (Cox & Lawless, 2000).
Furthermore, a study of HIV and hepatitis B and C prevalence among committal
prisoners (Long et al., 2000) found that of 175 prisoners with a history of injecting
drug use, only 23 per cent (n=41) reported that they had been fully vaccinated
for hepatitis B. There is also a need to ensure that drug users who begin a course
of the hepatitis B vaccination complete the three injections. In their study of HIV
and hepatitis B and C prevalence among the prison population, Allwright et al.
(1999) found that while 300 respondents reported that they had been vaccinated
against hepatitis B, only 184 had completed the three doses. 
2.6  Conclusion
There appears to be on-going evidence that a significant proportion of Irish drug
users may be infected with at least one drug-related infectious disease. However,
analysis of the situation remains restricted in the absence of comprehensive
routine data collection in the field. It would also appear that while harm-
reduction programmes have played a role in containing the spread of drug-
related infectious diseases to some extent, a significant proportion of Irish
injecting drug users are continuing to engage in risky behaviours. It would
appear that there is a need for more comprehensive education and information
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dissemination strategies targeted at drug users, and in particular young
injectors. Furthermore, there is a need for a more effective delivery of testing
services and, in particular, hepatitis B vaccination to drug users.
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